Fortrea Holdings Inc. (FTRE) vs Mineralys Therapeutics, Inc. (MLYS)
A side-by-side comparison of Fortrea Holdings Inc. and Mineralys Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FTRE
Fortrea Holdings Inc.
$21.88HealthcareDelayed quote: Oct 6, 2026, 11:10 AM EDT
MLYS
Mineralys Therapeutics, Inc.
$23.00HealthcareDelayed quote: Oct 6, 2026, 11:10 AM EDT
Total return — FTRE vs MLYS
growth of $100 · dividends reinvested · last 3yFTRE -34.0% (-12.9%/yr)MLYS +45.6% (+13.3%/yr)MLYS compounded faster over this window
FTRE MLYS
FTRE vs MLYS: by the numbers
- •FTRE is the larger company ($2.08B vs $2.03B market cap).
- •Both run net losses; MLYS's is the smaller (0.00% vs -3.18% net margin).
Metrics side by side
Valuation
| Metric | FTRE | MLYS |
|---|---|---|
| Forward P/E | 26.02 | N/A |
| P/S ratio | 0.78 | N/A |
| P/B ratio | 3.97 | 3.68 |
| EV / EBITDA | 33.93 | N/A |
| FCF yield | 7.24% | N/A |
Profitability
| Metric | FTRE | MLYS |
|---|---|---|
| Gross margin | 17.11% | 0.00% |
| Operating margin | 0.41% | 0.00% |
| Net margin | -3.18% | 0.00% |
| ROE | -16.25% | -63.45% |
| ROIC | 0.62% | -57.17% |
Growth (annualized)
| Metric | FTRE | MLYS |
|---|---|---|
| Revenue CAGR (5Y) | 1.09% | N/A |
| FCF CAGR (5Y) | -12.98% | N/A |
Go deeper
Dig into the metrics
Fortrea ROEMineralys Therapeutics ROEFortrea operating marginMineralys Therapeutics operating marginFortrea revenue growthMineralys Therapeutics revenue growthFortrea free cash flowMineralys Therapeutics free cash flow
Fortrea & Mineralys Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.